Elucidate The Genetic Backbone Of Individual Cancers
Recent technical breakthroughs in next generation sequencing technology with advanced bioinformatics analysis of cancer genomes have accelerated the convergence of discovery science and clinical medicine. Identification of genomic alteration that leads to cancer development will provide our understanding and classification of human tumors and accelerate the discovery of new approaches for clinical diagnosis, outcome prediction and risk stratification. Researchers in Diagnomics are translating information from cancer genomics into therapeutics and diagnostics that will revolutionize cancer treatment and management. We emphasize the importance of establishing the biological relevance of a cancer genomic discovery in realizing its clinical potential to make possible personalized cancer medicine.
Diagnomics is developing next generation sequencing (NGS) and advanced bioinformatics-based non-invasive cancer management systems that may provide the ultimate way to monitor and diagnose cancer recurrence and therapy effectiveness. The technology is based on proprietary quantitative cancer genome profiling and the detection of changes during the course of cancer treatment.
Individual Cancers And Underlying Mutations
The majority of human cancers are derived from sporadic tumors that arise through a multistage process in which somatic, genetic and epigenetic alterations lead to changes in gene sequence, structure, copy ibs number, and expression. High throughput sequencing of cancer tissue by next generation sequencing technology combined with advanced bioinformatics analysis enables a novel way of monitoring and diagnosing cancer in non-invasive testing*.
Cell-free DNA and RNA molecules circulating in human blood are very important early molecular diagnostic markers for cancer. Identification of tumor-derived circulating nucleic acids has been investigated for clinical oncology. The advent of NGS technologies has provided a superior approach for the detection, measurement and cataloging of circulating nucleic acids. Our proprietary Personalized Cancer Diagnosis (PCD) system which measures genomic mutation profile changes during the course of cancer treatment may provide unprecedented information from genome sequencing and advance bioinformatics analysis.
*US Patent Pending: Method for quantitating low levels of nucleic acids within high background for non-invasive diagnosis and disease monitoring.
